Stephen Restaino PhD named MDC Partner

The Maryland Development Center (MDC) is pleased to announce the promotion of Dr. Stephen M. Restaino, PhD to Partner.

Dr. Restaino is Vice-President and Director of Engineering at MDC, positions he will retain in his new role. Dr. Restaino joins the MDC Partnership consisting of eight clinicians from the University of Maryland School of Medicine and Gil Blankenship, the engineer/entrepreneur who founded MDC in 2016.

Dr. Restaino earned his Ph.D. from the Fischell Department of Biomedical Engineering from the University of Maryland, College Park. He joined MDC in 2017 and has been involved in every MDC project during his time here. He is the co-inventor of several MDC technologies, and is the co-founder and Interim CEO of MDC spinout company Sonosa Medical Inc.

“Stephen has been an integral part of the growth of MDC since his arrival. His remarkable insight and leadership of the engineering team and his skills as a business leader led the Partnership to elect him as a partner and shareholder in MDC. We are looking forward to supporting Stephen in the development of the Sonosa technology and startup company,” said Dr. Gil Blankenship, Founder of MDC.

About the MDC Studio

The MDC Studio is the operational unit of the Maryland Development Center Partnership, which was founded in 2016 in Baltimore, Maryland. MDC Studio functions as a MedTech Startup Studio that provides engineering support, business development services, and funding to create and support companies commercializing medical devices. The Studio works with inventors to develop their ideas into working prototypes and marketable products and form companies that will grow and create value for both their shareholders and all of society. MDC Studio Baltimore is located in the historic Wilkens-Robins building in the heart of Baltimore, near the University of Maryland Medical Center, and Johns Hopkins University where MDC’s founding partners and affiliates practice, teach, and research state of the art surgery and medicine.